bioAffinity Technologies Announces 100% Increase In Sales For Its CyPath Lung Test For Lung Cancer

bioAffinity Technologies To Present New Data On Sputum-Based Tests In Development To Characterize Lung Inflammation And Detect Multiple Protein Biomarkers Of Lung Inflammation At CHEST 2026

Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targetsCompany advances research and development in diagnostic tests for major lung diseases

BIAF stock has given up its prior gain. bioAffinity Technologies shares were trading higher after the company announced that the Japan Patent Office issued a Notice of Allowance indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer powered by the CyPath Lung test for early-stage lung cancer.

bioAffinity Technologies Commences ~$4M Offering Of Common Stock At $6.122 Per Share

bioAffinity Technologies shares are trading higher after the company announced that the Japan Patent Office issued a Notice of Allowance indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer powered by the CyPath Lung test for early-stage lung cancer.